High and rising prescription drug prices force consumers to skip doses or even avoid filling their prescriptions for life-saving medications altogether. Now is the perfect time for Congress to finally begin to take action by passing the bipartisan CREATES Act.
High prescription drug prices hurt families and consumers by adding financial stress to devastating illness.
States have led the way to take action against high and rising drug prices, and with the help of advocates this action can continue and grow in 2019.
On this webinar, we explore options and approaches to state drug pricing policy, including a special focus on how states can build upon the success of price transparency laws to provide meaningful information that spurs broader changes.
2018 has been a year of opportunity when it comes to state legislation to address the high and rising prices of prescription drugs. Families USA has identified some of the 2018 state legislative sessions’ biggest victories on the issue of prescription drug costs, along with significant legislation considered in the 2018 session that may be on the agenda again in 2019.
Families USA has identified some of the biggest legislative victories for health care in the 2018 state legislative sessions.
Last week, the Trump administration announced a second round of drug pricing proposals that, while relatively modest on their own, take important steps toward future reforms that could significantly reduce prices now burdening both consumers and the overall health care system.
41 Consumer and Patient Groups Urge the Trump Administration to Take Real Action on Prescription Drugs
Families USA, Public Citizen, and 39 other national and state-based organizations including the Services Employees International Union, the National Partnership for Women and Families, the AFL-CIO, AFSCME, and NETWORK Lobby for Catholic Social Justice submitted a comment letter in response to the Request for Information (RFI) from the Trump Administration regarding HHS’ Blueprint on Prescription Drug Costs.
After candidate and then President Trump repeatedly promised to slash prescription drug prices, the May 11 announcement of administration drug policy was a significant missed opportunity.
One Illinois legislator is taking action so that residents in his state will no longer have to suffer without recourse when generic drug manufacturers engage in the practice of price gouging. Families USA has been proud to work with State Representative Will Guzzardi from Illinois’ 39th District on HB 4900, legislation that Rep. Guzzardi introduced in the state legislature to create generic drug pricing fairness and stop price gouging in Illinois.
Here Families USA interviews Rep. Guzzardi on how high prescription drug prices hurt Illinois families, and how HB 4900 will help make drugs more affordable in the state.
As drug prices continue to rise at an unsustainable rate, we must ensure that our health care system and its financial incentives enhance the quality and value of care. We believe the Medicare Part B prescription drug model proposed by the Centers for Medicare & Medicaid Services (CMS) creates value for the patient and the program by encouraging treatment choices that have been shown to improve care and health outcomes.